Secondary metastatic lesions to colon and rectum

Michail Galanopoulosa, Filippos Gkerosa, Christos Liatsosb, Christos Pontasa, Apostolis Papaeftymioud, Nikos Viazisa, Gerassimos J. Mantzarisa, Nikolaos Tsoukalasd

Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals; 401 General Military Hospital; Veterans Hospital 417 NIMTS, Athens, Greece

Abstract

Metastatic lesions of the colon are a rare clinical entity that may present difficulties in management. The incidence of these metastases appears to be increasing, as a result of physicians’ greater awareness during follow-up investigations of a primary neoplasm. Furthermore, the presence of a greater proportion of these abnormalities at autopsy should be a triggering factor for further investigation for doctors dealing with colorectal oncology. Their clinical presentation may vary from asymptomatic to signs similar to those of colorectal cancer. However, immunohistological analysis is considered the cornerstone for differentiating metastases to the colon, originating from other primaries, from primary colorectal neoplasms. Survival reports and treatment options vary. This article concisely presents the main characteristics of the secondary lesions to the colon from neoplasms that metastasize to the large intestine (namely, lung, ovary, breast, prostate, kidney, and melanoma) focusing on their incidence, their clinical presentation and the workup investigation. Physicians aware of this uncommon entity are much better prepared to apply an efficient diagnosis and workup, as well as an appropriate treatment strategy.

Keywords Metastatic lesions to colorectum, lung cancer, ovarian cancer, breast cancer, prostate cancer, renal cancer, melanoma

Introduction

Colorectal cancer (CRC) is the most common neoplasia in the gastrointestinal (GI) tract and the third most frequent malignancy worldwide, with an incidence approaching 1.5 million cases annually [1,2]. Furthermore, it is considered that over 600,000 deaths each year are attributable to tumors of the large intestine, making them the third cause of cancer-related deaths [3]. In contrast, metastatic neoplasms in the colon are an uncommon entity, emerging in approximately 1% of total colorectal cancers [4]. Although colonic metastases are generally a rare incidence, post-mortem investigations demonstrate a greater occurrence than expected [5,6].

Secondary involvement of colorectum is often diagnosed in patients with a known primary neoplasm, usually deriving from the lung, ovary, breast, prostate, kidney, skin, stomach, or hepatobiliary system [7,8]. In most cases there are multiple lesions; however, one third of them may still be asymptomatic or found only at autopsy. The commonest pathway of metastatic spreading to the bowel is through peritoneal seeding (typical of ovarian cancer), though hematogenous and lymphatic dissemination to the colon has also been reported, as in breast carcinoma, lung carcinoma, and melanoma (Fig. 1) [5,9-11].

As regards the clinical presentation of metastatic lesion to colon, they may present with bowel obstruction, lower GI bleeding, anemia, and weight loss, though exuberant symptomatology is considered uncommon [12]. Acute abdomen is even rarer, with limited survival rates [7,8,13,14]. On the other hand, a third of such colonic metastases are asymptomatic or found only at autopsy, as mentioned above.

Therefore, the aim of this manuscript was to present a brief review of the most prevalent primary malignancies (namely, lung, ovary, breast, prostate, kidney, and melanoma) that metastasize to the colon, focusing on their frequency, their clinical presentation and the workup investigation. With regard to the latter, the histological and immunochemical study of...
specimens derived from colon biopsies seems to be the most crucial factor in the differential diagnosis of secondary tumors to the colon from other colorectal neoplasms (Table 1).

Materials and methods

An extensive English-language literature search was conducted using PubMed to identify original studies and review articles, using as keywords "metastatic lesions to colorectum", "lung cancer", "ovarian cancer", "breast cancer", "prostate cancer", "renal cancer", "melanoma".

Lung cancer (LC) metastatic to colon

LC is the leading cause of cancer-related deaths in men and the second most common in women after breast cancer [15]. The most commonly involved organs of LC metastasis are the thoracic lymph nodes, liver, adrenal glands, brain, pleura, kidneys, and bones. The GI tract is an extremely rare field of LC metastasis and few cases have been reported [13,16-25]. In this context, Antler et al., in a separate autopsy series of 423 patients, found an overall 14% (58 cases) involvement of the GI tract from metastatic LC [19]. Of these, a majority (46%) were secondary to the direct infiltration of the esophageal wall, while the small and large bowel were involved in only 6% of the cases.

Colonic metastatic disease should be considered when a patient with LC presents with bowel obstruction, perforation, GI fistula, microcytic anemia, bleeding, and rarely bowel intussusception [26]. Therefore, it is deduced that there is no pathognomonic symptom that can lead us to the diagnosis of metastasis from primary LC to the large intestine. On the contrary, it seems that, based on the symptoms and the rarity of metastasis from lung to colon, it is very difficult to distinguish if the colon is the primary cancer site or a metastasis from LC.

Diagnosis of secondary disease of LC to colon can be made by radiological examination and/or endoscopy of the lower GI tract. Diagnostic tests such as computed tomography (CT) of the abdomen can reveal thickening of the bowel, whereas colonoscopy mainly shows a lesion of the intestinal wall that may cause bowel obstruction. During colonoscopy, biopsies should be taken to determine whether the cancer has metastasized from lung to colon. Immunohistochemistry is of utmost importance for the diagnosis and the differentiation of metastatic from primary colonic malignancy. Colorectal adenocarcinoma is typically CDX-2 positive, cytokeratin (CK) 20 positive, and CK7 negative. Most primary lung malignancies are TTF-1 positive, CK7 positive, and CK20 negative [27].

In conclusion, even though metastases from lung to large bowel exhibit a diminutive incidence, when patients with a history of LC diagnosis and/or treatment present with GI symptoms (pain, bleeding, acute abdomen, obstruction), the possibility of colonic secondary disease should be part of our differential diagnosis [26].

Ovarian cancer metastatic to colon

Ovarian cancer is the sixth most common malignancy worldwide, with an incidence of 11 in 100,000 people in Europe, being the most lethal gynecological cancer [28]. It mainly metastasizes to the pelvis, peritoneum and omentum, as well as the contralateral ovary and sigmoid colon. Distant extraperitoneal metastases are considered an extremely rare phenomenon [29]. Colonic metastases of ovarian origin account for 4-6% of cases [4,30]. The interval between the initial diagnosis and the development of metastases ranges from 1-22 years, with a mean of 9 years [31], whilst the age of affected patients ranges from 34-77 years, with a mean of 58.8 years [32]. Furthermore, it should be highlighted that certain cases have been described where the presence of colonic metastasis was synchronous with ovarian carcinoma (Table 2) [33-38].

<table>
<thead>
<tr>
<th>Primary neoplasm</th>
<th>Tumor marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>TTF-1 positive CK7 positive and CK20 negative</td>
</tr>
<tr>
<td>Ovarian</td>
<td>Positive for CK 7, CA-125, estrogen and progesterone receptors</td>
</tr>
<tr>
<td>Breast</td>
<td>Expression of estrogen- or progesterone-receptors Loss of expression of cell-to-cell E-cadherin Overexpression of HER2, cytokeratins (AE1/AE3, 7), Ki67, p53, and histiocytic markers (CD68)</td>
</tr>
<tr>
<td>Prostate</td>
<td>Expression of P501S protein or prostate-specific membrane antigen</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Expression of S-100 protein, Melan-A and HMB-45</td>
</tr>
</tbody>
</table>

**Table 1 Evaluation of immunohistochemical markers indicative of primary tumors (other than CRC) which can metastasize to colorectum**

CRC, colorectal cancer; TTF, thyroid transcription factor; CK, cytokeratin; HER, human epidermal receptor; HMB, human melanoma black
The pathway of dissemination of ovarian neoplasm to the colon and rectum may involve four different routes: lymphogenous, hematogenous, by direct infiltration of the bowel wall, or by spreading through the peritoneum [39]. The latter, known as the transcoelomic route, provides the most plausible pathophysiologic explanation for secondary disease to the colon.

Clinical manifestations of metastatic disease can be obscure; hence, patients may present abdominal discomfort, bowel obstruction or intussusception, a palpable abdominal mass, or may even be free of symptoms [31-33,39]. Diagnostic evaluation includes imaging, such as abdominal CT or ultrasonography, which can reveal unilateral or bilateral masses in the pelvis, regional lymphadenopathy, ascites or a mass on the colonic wall or intraluminally [30]. Endoscopy and subsequent assessment of biopsies are necessary for the diagnosis and identification of the tumor origin [30,33,40,41]. Finally, immunohistochemical evaluation with tumor markers, namely CEA, CA-125, CA 19-9, CK7 and CK20, estrogen and progesterone receptors, is paramount for the identification of the origin of the metastasis. Specifically, immunohistochemical staining positive for CK7, CA-125, estrogen and progesterone receptors is considered indicative of ovarian origin. On the other hand, a CK20 and CEA positive stain hints at a colorectal origin [30]. Interestingly, though a CK7 positive/CK20 negative immunophenotype is very unlikely to demonstrate a primary colon malignancy, CK7-/CK20+ phenotype is usually found in CRC biopsies [33,41].

Breast cancer metastatic to colon

Breast cancer is considered as a common entity in oncology, accounting for approximately 32% of the total number of neoplasms, being at the same time a major mortality factor for women. Despite an increase in survival, which can be attributed to earlier diagnosis and improved therapeutic approach, it is estimated that 30% of patients will develop distant metastases, even after treatment. GI tract metastases are relatively rare, with some studies reporting colon involvement in between 3% and 12% of cases [42-45]. They are associated with extensive disease and poor survival rates [46]. The most common histopathological subtype of GI tract metastasis seems to be invasive lobular carcinoma, which constitutes a mere 5-15% of total breast neoplasms (Table 3) [10,47-54]. The interval between the diagnosis of lobular carcinoma and colon metastasis is approximately 20-30 years [55]. Pathophysiologically, the main pathway responsible for colonic disease is hematogenous

<table>
<thead>
<tr>
<th>Case</th>
<th>Year</th>
<th>Age</th>
<th>Site of metastasis</th>
<th>Histological type of breast malignancy</th>
<th>Months to diagnosis</th>
<th>Survival (months)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1997</td>
<td>43</td>
<td>Ascending</td>
<td>Ductal/lobular mixed type</td>
<td>42</td>
<td>NA</td>
<td>[48]</td>
</tr>
<tr>
<td>2</td>
<td>1998</td>
<td>66</td>
<td>Ascending</td>
<td>Lobular</td>
<td>72</td>
<td>16</td>
<td>[10]</td>
</tr>
<tr>
<td>3</td>
<td>2000</td>
<td>65</td>
<td>Ascending</td>
<td>Lobular</td>
<td>48</td>
<td>36</td>
<td>[10]</td>
</tr>
<tr>
<td>4</td>
<td>2003</td>
<td>80</td>
<td>Sigmoid</td>
<td>Lobular</td>
<td>300</td>
<td>9</td>
<td>[49]</td>
</tr>
<tr>
<td>5</td>
<td>2006</td>
<td>70</td>
<td>Ileocecal valve</td>
<td>Lobular</td>
<td>5</td>
<td>NA</td>
<td>[10]</td>
</tr>
<tr>
<td>6</td>
<td>2008</td>
<td>61</td>
<td>Sigmoid</td>
<td>Lobular</td>
<td>81</td>
<td>NA</td>
<td>[50]</td>
</tr>
<tr>
<td>7</td>
<td>2008</td>
<td>72</td>
<td>Cecum</td>
<td>Ductal</td>
<td>36</td>
<td>NA</td>
<td>[51]</td>
</tr>
<tr>
<td>8</td>
<td>2008</td>
<td>70</td>
<td>Rectum</td>
<td>Lobular</td>
<td>4</td>
<td>NA</td>
<td>[52]</td>
</tr>
<tr>
<td>9</td>
<td>2011</td>
<td>70</td>
<td>Rectum</td>
<td>Lobular</td>
<td>Synchronous</td>
<td>12</td>
<td>[53]</td>
</tr>
<tr>
<td>10</td>
<td>2016</td>
<td>55</td>
<td>Entire colon</td>
<td>Lobular</td>
<td>Synchronous</td>
<td>NA</td>
<td>[54]</td>
</tr>
</tbody>
</table>

**Table 2** Clinical characteristics of published colonic metastases from primary ovarian cancer

<table>
<thead>
<tr>
<th>Case</th>
<th>Year</th>
<th>Age</th>
<th>Site of metastasis</th>
<th>Pathology</th>
<th>Endoscopic appearance</th>
<th>Years to diagnosis</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2004</td>
<td>39</td>
<td>Sigmoid</td>
<td>Papillary serous/endometrioid mixed type adenocarcinoma</td>
<td>Polypoid mass</td>
<td>0.5</td>
<td>[34]</td>
</tr>
<tr>
<td>2</td>
<td>2009</td>
<td>69</td>
<td>Rectum</td>
<td>Papillary serous adenocarcinoma</td>
<td>Elevated irregular lesion</td>
<td>20</td>
<td>[31]</td>
</tr>
<tr>
<td>3</td>
<td>2012</td>
<td>75</td>
<td>Rectum</td>
<td>Serous adenocarcinoma</td>
<td>Firm, irregular mucosal abnormality</td>
<td>6</td>
<td>[35]</td>
</tr>
<tr>
<td>4</td>
<td>2012</td>
<td>50</td>
<td>Rectum</td>
<td>Papillary serous adenocarcinoma</td>
<td>Elevated irregular lesion with ulceration</td>
<td>Synchronous</td>
<td>[36]</td>
</tr>
<tr>
<td>5</td>
<td>2012</td>
<td>60</td>
<td>Sigmoid</td>
<td>Papillary serous adenocarcinoma</td>
<td>Polypoid lesion</td>
<td>Synchronous</td>
<td>[37]</td>
</tr>
<tr>
<td>6</td>
<td>2012</td>
<td>56</td>
<td>Rectum</td>
<td>Papillary serous adenocarcinoma</td>
<td>Polypoid lesion</td>
<td>Synchronous</td>
<td>[37]</td>
</tr>
<tr>
<td>7</td>
<td>2013</td>
<td>70</td>
<td>Rectosigmoid junction</td>
<td>Papillary serous adenocarcinoma</td>
<td>Fungating mass</td>
<td>8</td>
<td>[38]</td>
</tr>
</tbody>
</table>

**Table 3** Clinical characteristics of published colonic metastases from primary breast cancer
dissemination; however, peritoneal and lymphatic spreading have been documented [56].

Clinical manifestations of metastatic lobular breast carcinoma to the colon are frequently non-specific and can usually pose a diagnostic challenge, as they can quite often imitate acute or chronic inflammatory processes, such as diverticulitis and inflammatory bowel diseases, or may mimic primary colonic tumors. Further diagnostic tests, such as radiology or endoscopy, are essential for an accurate diagnosis and treatment. CT imaging of the abdomen can reveal thickening of the intestinal wall, possibly with nodal infiltration [47]. Colonoscopy may reveal an abnormal lumen appearance, such as an intraluminal obstructing lesion or even multiple polypoid lesions [49,54]. Hence, female patients presenting new GI lesions, microcytic anemia and/or vague GI symptoms, especially those with a history of breast neoplasm, should be rigorously evaluated towards metachronous malignant lesions in the large intestine through pathologic evaluation and immunohistochemical analysis.

Histopathological examination of metastatic lobular breast carcinoma shows a typical pattern of invasion, with intramural infiltration throughout the submucosa, muscular propria and serosa. Tumor cells grow to form cords (Indian files) or small clusters [53,54]. They commonly present a signet-ring appearance. The absence of dysplasia or nuclear atypia in the colonic epithelium and the presence of infiltrating tumoral cells surrounding the preexistent glands is consistent with the diagnosis of metastatic tumor. Immunohistochemical study can help to rule out neoplasms with similar appearance, such as intestinal signet-ring cell carcinoma. More importantly, immunostaining can reveal the expression of estrogen or progesterone receptors and the loss of expression of cell-to-cell E-cadherin, consistent with the unique dispersion pattern of lobular carcinoma, in contrast to that of ducal carcinoma. Other immunohistochemical markers include overexpression of HER2, cytokeratins (AE1/AE3, 7), ki67, p53, and histiocytic markers (CD68), which can contribute to an accurate diagnosis by comparison to the immunophenotype of the breast neoplasm [47,55].

**Prostate cancer (PCA) metastatic to colon**

It is well known that two of the most prevalent tumors among adult males are PCA and CRC [57]. Although rare, the anatomical adjacency of these two organs predisposes to locoregional penetration by a locally advanced PCA with an occurrence of 1-12% [58]. This dissemination occurs through three different routes: direct invasion through Denovilliers’ fascia and rectal infiltration; lymphatic spread through the common pelvic lymph node channels; and implantation along a needle biopsy tract in rectal or perirectal tissue [59, 60]. The vast majority of metastases are localized to the sigmoid and rectum.

The clinical presentation includes any possible manifestation that a colorectal mass might present with. The absence of specific symptoms, in combination with the long interval between the initial PCA diagnosis and metastasis presentation (combined with a lack of serum prostate-specific antigen elevation in many cases), may often lead to an incorrect diagnosis of CRC. Lane et al, who studied 23 patients with a diagnosis of PCA metastasized to colon, reported that 19 of them had a PCA diagnosis 2-18 years before colorectal metastasis, whereas the remaining 4 patients had initially presented with lower GI symptoms [61]. Regarding the histological workup, signs of prostatic colonization, such as the presence of microacinar or acinar architecture and extensive lymphovascular invasion, are absent in most cases. Immunohistochemical investigation reveals a metastasis in case of the presence of at least one prostate-specific marker (PS01S protein or prostate-specific membrane antigen) combined with the lack of markers of colonic differentiation [61,62].

**Renal cancer metastatic to colon**

Renal cell carcinoma (RCC) is the commonest renal cancer in adults and can exhibit metastatic spreading in almost 40% of cases, even after a radical excision [63]. Solitary metastasis has been reported in less than 10% of cases. Lungs, liver, bones and brain are the major target organs of metastatic renal disease, whilst less than 10 cases present secondary disease to the colon [64,65].

The range of symptoms and signs during the clinical assessment of colorectal metastases is wide and roughly identical with those of CRC, including mainly lower GI bleeding [64]. Likewise, findings of colonoscopy and biopsy specimens are nonspecific, as the current bibliography reveals. Additionally, the location of metastases in the large intestine does not provide useful information; lesions have been found along the entire colon, from cecum to rectum. In contrast, pathologic findings of late recurrences tend to be unique and are often associated with primary renal tumors of T2 stage or greater, being poorly differentiated [63].

A high level of clinical suspicion is required to track colorectal metastasis of RCC, because there are no definite guidelines for surveillance beyond 5 years postoperatively. However, a long-term longitudinal study of 3651 patients after surgery for M0 RCC showed that up to a third of RCC recurrences would have been missed if the guidelines of the National Comprehensive Cancer Network and American Urological Association were strictly followed [66]. Consequently, the increased likelihood of a late RCC recurrence requires the extension of postoperative monitoring.

**Melanoma metastatic to colon**

Melanoma is a type of skin cancer originating from the pigment-producing melanocytes in the basal layer of the epidermis [67]. The main cause of melanomas is ultraviolet radiation and the primary site of appearance is the skin (especially for those with “Type I” skin) [68,69]. Several rare genetic defects can also increase the risk [70]. Other common sites of primary lesions are the mouth, the eyes, and the GI tract (mainly the esophagus and the stomach) [68,69]. The tumor spreads through the lymph and the distant organs mostly affected are the liver, the lungs, the bones, and the brain [71]. Although
melanoma metastasizes frequently to the GI tract (esophagus and stomach are the commonest sites), secondary colonic disease is rare. A study by Giuliano et al showed that, in 980 patients with metastasis from melanoma of unknown primary site, less than 7% had metastasis to the colon [72]. The absence of melanocytes in the colon, apart from the anorectal region, is probably the main reason that colonic metastases of melanoma rarely occur [73].

The most common sign of colonic metastasis in patients with melanoma is intestinal bleeding and obstruction or perforation [74]. Most colonic metastases are discovered after a CT or positron emission tomography-CT during regular surveillance. These patients undergo a colonoscopy because of its high sensitivity and specificity. Endoscopy with biopsies has an essential role in the diagnosis and identification of the tumor's origin, which helps define the treatment that the patient will receive. Most melanomas have immunohistochemical staining positive for S-100 protein, Melan-A and HMB-45 [75].

**Concluding remarks**

Colorectal malignancies are considered amongst the deadliest to date, even though various techniques are available to prevent and detect their occurrence. Nevertheless, their detection, especially metastatic lesions to the colon, may be a difficult issue for physicians to resolve because of their rarity. Therefore, great awareness is needed during workup investigations and subsequent follow-up examinations for primary neoplasms, so as to prevent secondary pathologies to the colorectum. Thus, with this review we tried to highlight the main epidemiological, clinical, and histopathological features of metastatic disease from the most prevalent primary neoplasms presenting in the colorectum.

**References**

Annals of Gastroenterology 31


